Diaceutics (LON:DXRX) Shares Down 1.8% – Here’s What Happened

Diaceutics PLC (LON:DXRX) was down 1.8% on Thursday . The stock traded as low as GBX 133 and last traded at GBX 133. Approximately 43,656 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 176,776 shares. The stock had previously closed at GBX 135.50.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group boosted their price objective on Diaceutics from GBX 215 to GBX 216 and gave the stock a “buy” rating in a report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics presently has an average rating of “Buy” and a consensus target price of GBX 215.50.

Diaceutics Price Performance

The firm has a market capitalization of £112.56 million, a PE ratio of 1,209.09 and a beta of 0.89. The business has a 50-day moving average of GBX 149.98 and a 200 day moving average of GBX 153.53. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85.

Diaceutics (LON:DXRX) last posted its quarterly earnings data on Tuesday, May 26th. The company reported GBX 11 earnings per share (EPS) for the quarter. The firm had revenue of GBX 3,844 million for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. As a group, research analysts anticipate that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.